Literature DB >> 15332247

Evaluation of heart perfusion in patients with acute myocardial infarction using dynamic contrast-enhanced magnetic resonance imaging.

Gitte Nielsen1, Thomas Fritz-Hansen, Christina G Dirks, Gorm B Jensen, Henrik B W Larsson.   

Abstract

PURPOSE: To investigate the diagnostic ability of quantitative magnetic resonance imaging (MRI) heart perfusion in acute heart patients, a fast, multislice dynamic contrast-enhanced MRI sequence was applied to patients with acute myocardial infarction.
MATERIALS AND METHODS: Seven patients with acute transmural myocardial infarction were studied using a Turbo-fast low angle shot (FLASH) MRI sequence to monitor the first pass of an extravascular contrast agent (CA), gadolinium diethylene triamine pentaacetic acid (Gd-DTPA). Quantitation of perfusion, expressed as Ki (mL/100 g/minute), in five slices, each having 60 sectors, provided an estimation of the severity and extent of the perfusion deficiency. Reperfusion was assessed both by noninvasive criteria and by coronary angiography (CAG).
RESULTS: The Ki maps clearly delineated the infarction in all patients. Thrombolytic treatment was clearly beneficial in one case, but had no effect in the two other cases. Over the time-course of the study, normal perfusion values were not reestablished following thrombolytic treatment in all cases investigated.
CONCLUSION: This study shows that quantitative MRI perfusion values can be obtained from acutely ill patients following acute myocardial infarction. The technique provides information on both the volume and severity of affected myocardial tissue, enabling the power of treatment regimes to be assessed objectively, and this approach should aid individual patient stratification and prognosis. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332247     DOI: 10.1002/jmri.20142

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Quantitative myocardial distribution volume from dynamic contrast-enhanced MRI.

Authors:  Nathan A Pack; Edward V R Dibella; Brent D Wilson; Christopher J McGann
Journal:  Magn Reson Imaging       Date:  2008-02-20       Impact factor: 2.546

Review 2.  Echocardiography and cardiovascular magnetic resonance: evolution as complementary imaging tools.

Authors:  Ramdas G Pai; Padmini Varadarajan
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

3.  Comparison of myocardial perfusion estimates from dynamic contrast-enhanced magnetic resonance imaging with four quantitative analysis methods.

Authors:  Nathan A Pack; Edward V R DiBella
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

4.  MR first pass perfusion of benign and malignant cardiac tumours-significant differences and diagnostic accuracy.

Authors:  K U Bauner; S Sourbron; M Picciolo; C Schmitz; D Theisen; T A Sandner; M F Reiser; A M Huber
Journal:  Eur Radiol       Date:  2011-08-26       Impact factor: 5.315

Review 5.  Quantitative myocardial perfusion imaging by cardiovascular magnetic resonance and positron emission tomography.

Authors:  K Bratis; I Mahmoud; A Chiribiri; E Nagel
Journal:  J Nucl Cardiol       Date:  2013-07-19       Impact factor: 5.952

6.  Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus.

Authors:  Erik B Schelbert; Stephen M Testa; Christopher G Meier; William J Ceyrolles; Joshua E Levenson; Alexander J Blair; Peter Kellman; Bobby L Jones; Daniel R Ludwig; David Schwartzman; Sanjeev G Shroff; Timothy C Wong
Journal:  J Cardiovasc Magn Reson       Date:  2011-03-04       Impact factor: 5.364

7.  Markers of human endometrial hypoxia can be detected in vivo and ex vivo during physiological menstruation.

Authors:  J J Reavey; C Walker; M Nicol; A A Murray; H O D Critchley; L E Kershaw; J A Maybin
Journal:  Hum Reprod       Date:  2021-03-18       Impact factor: 6.918

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.